Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 964 participants.
Also called NCT01042977
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 964 participants
- Sponsor
- Registry
-
NCT01042977
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Bulgaria, Canada, Chile, Germany, Hungary, Poland
- Registry status
- Completed
Technical summary
Registry record NCT01042977. Randomized; quadruple masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2011-05 (actual). Results posted on 2013-08-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Cardiovascular Disease
- Condition
- Inadequate Glycaemic Control
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
- Collaborator
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct01042977- Content hash
609f13079d2778ce5959ec2fb0a8096cba7239f57c06bbf801349215b61c2c92